Cargando…
Blood Protein Markers of Neocortical Amyloid-β Burden: A Candidate Study Using SOMAscan Technology
Background: Four previously reported studies have tested for association of blood proteins with neocortical amyloid-β burden (NAB). If shown to be robust, these proteins could have utility as a blood test for enrichment in clinical trials of Alzheimer’s disease (AD) therapeutics. Objective: This stu...
Autores principales: | Voyle, Nicola, Baker, David, Burnham, Samantha C., Covin, Antonia, Zhang, Zhanpan, Sangurdekar, Dipen P., Tan Hehir, Cristina A., Bazenet, Chantal, Lovestone, Simon, Kiddle, Steven, Dobson, Richard J.B. |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
IOS Press
2015
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4923714/ https://www.ncbi.nlm.nih.gov/pubmed/25881911 http://dx.doi.org/10.3233/JAD-150020 |
Ejemplares similares
-
Blood metabolite markers of neocortical amyloid-β burden: discovery and enrichment using candidate proteins
por: Voyle, N, et al.
Publicado: (2016) -
Blood protein predictors of brain amyloid for enrichment in clinical trials?
por: Ashton, Nicholas J., et al.
Publicado: (2015) -
Discovery and validation of plasma proteomic biomarkers relating to brain amyloid burden by SOMAscan assay
por: Shi, Liu, et al.
Publicado: (2019) -
Genetic Risk as a Marker of Amyloid-β and Tau Burden in Cerebrospinal Fluid
por: Voyle, Nicola, et al.
Publicado: (2016) -
Assessment of Variability in the SOMAscan Assay
por: Candia, Julián, et al.
Publicado: (2017)